 Oligopeptides
"Oligopeptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptides composed of between two and twelve amino acids.
| Descriptor ID |
D009842
|
| MeSH Number(s) |
D12.644.456
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Oligopeptides".
Below are MeSH descriptors whose meaning is more specific than "Oligopeptides".
This graph shows the total number of publications written about "Oligopeptides" by people in this website by year, and whether "Oligopeptides" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1984 | 1 | 3 | 4 | | 1985 | 1 | 1 | 2 | | 1986 | 1 | 1 | 2 | | 1989 | 0 | 1 | 1 | | 1990 | 1 | 1 | 2 | | 1991 | 2 | 0 | 2 | | 1992 | 3 | 0 | 3 | | 1993 | 0 | 3 | 3 | | 1994 | 1 | 2 | 3 | | 1995 | 3 | 0 | 3 | | 1996 | 3 | 1 | 4 | | 1997 | 1 | 0 | 1 | | 1998 | 1 | 3 | 4 | | 1999 | 3 | 2 | 5 | | 2000 | 0 | 4 | 4 | | 2001 | 2 | 2 | 4 | | 2002 | 0 | 1 | 1 | | 2003 | 2 | 1 | 3 | | 2004 | 1 | 4 | 5 | | 2005 | 4 | 1 | 5 | | 2006 | 1 | 1 | 2 | | 2007 | 5 | 1 | 6 | | 2008 | 1 | 2 | 3 | | 2009 | 2 | 1 | 3 | | 2010 | 2 | 3 | 5 | | 2011 | 5 | 2 | 7 | | 2012 | 5 | 7 | 12 | | 2013 | 3 | 5 | 8 | | 2014 | 7 | 2 | 9 | | 2015 | 2 | 1 | 3 | | 2016 | 3 | 4 | 7 | | 2017 | 5 | 3 | 8 | | 2018 | 2 | 1 | 3 | | 2019 | 4 | 3 | 7 | | 2020 | 0 | 4 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Oligopeptides" by people in Profiles.
-
Landgren O, Siegel D, Kazandjian D, Costa L, Jakubowiak A. Treatments for newly diagnosed multiple myeloma: when endurance is interrupted. Lancet Oncol. 2020 12; 21(12):e540.
-
Jasielec JK, Kubicki T, Raje N, Vij R, Reece D, Berdeja J, Derman BA, Rosenbaum CA, Richardson P, Gurbuxani S, Major S, Wolfe B, Stefka AT, Stephens L, Tinari KM, Hycner T, Rojek AE, Dytfeld D, Griffith KA, Zimmerman TM, Jakubowiak AJ. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020 11 26; 136(22):2513-2523.
-
Deak P, Kimani F, Cassaidy B, Esser-Kahn A. Determining Whether Agonist Density or Agonist Number Is More Important for Immune Activation via Micoparticle Based Assay. Front Immunol. 2020; 11:642.
-
Xu XS, Moreau P, Usmani SZ, Lonial S, Jakubowiak A, Oriol A, Krishnan A, Bladé J, Luo M, Sun YN, Zhou H, Nnane I, Deraedt W, Qi M, Ukropec J, Clemens PL. Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. Adv Ther. 2020 04; 37(4):1464-1478.
-
He YJ, Santana MF, Moucka M, Quirk J, Shuaibi A, Pimentel MB, Grossman S, Rashid MM, Cinar A, Georgiadis JG, Vaicik MK, Kawaji K, Venerus DC, Papavasiliou G. Immobilized RGD concentration and proteolytic degradation synergistically enhance vascular sprouting within hydrogel scaffolds of varying modulus. J Biomater Sci Polym Ed. 2020 02; 31(3):324-349.
-
Hari P, Matous JV, Voorhees PM, Shain KH, Obreja M, Frye J, Fujii H, Jakubowiak AJ, Rossi D, Sonneveld P. Oprozomib in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2019 08 16; 9(9):66.
-
Landgren O, Sonneveld P, Jakubowiak A, Mohty M, Iskander KS, Mezzi K, Siegel DS. Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Leukemia. 2019 09; 33(9):2127-2143.
-
Ghobrial IM, Vij R, Siegel D, Badros A, Kaufman J, Raje N, Jakubowiak A, Savona MR, Obreja M, Berdeja JG. A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia. Clin Cancer Res. 2019 08 15; 25(16):4907-4916.
-
Jakubowiak AJ, Jasielec JK, Rosenbaum CA, Cole CE, Chari A, Mikhael J, Nam J, McIver A, Severson E, Stephens LA, Tinari K, Rosebeck S, Zimmerman TM, Hycner T, Turowski A, Karrison T, Zonder JA. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol. 2019 08; 186(4):549-560.
-
Chari A, Martinez-Lopez J, Mateos MV, Bladé J, Benboubker L, Oriol A, Arnulf B, Rodriguez-Otero P, Pineiro L, Jakubowiak A, de Boer C, Wang J, Clemens PL, Ukropec J, Schecter J, Lonial S, Moreau P. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2019 08 01; 134(5):421-431.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|